Skip navigation.

Investments

Details of our portfolio appear below.

- Acrobot -

Acrobot is a spin-out from Imperial Innovations Group plc. The founders included Brian Davis, Professor of Medical Robotics in the Department of Mechanical Engineering at Imperial College London and Justin Cobb, Professor of Orthopaedics at Imperial College London and a surgeon at Charing Cross Hospital, London. The Company’s products and services centre on the application of computer science, mechanical, electrical, and electronics engineering disciplines to surgery. The early focus of the Company was on the development of hands-on robotic solutions and this work ultimately led to the evolution of the Acrobot Modeller, Acrobot Planner and Acrobot Navigator products. Following a funding round in July 2007, Acrobot has moved forward fully to commercialise its Modeller, Planner and Navigator products in orthopaedics and to accelerate development of its exciting bone sculpting robotic solution, Acrobot Sculptor®. The Acrobot Sculptor® system is a motorised programmable device based on Acrobot’s key ‘Active Constraint’ patented technology, which prevents the surgeon accidentally moving a bone cutting tool outside a specified area. LTF first co-led a syndicate investing in Acrobot in July 2007 and has subsequently co-led the syndicate in providing follow-on funding. This syndicate has now invested over £3m.

For more information, please see latest news, our press release and www.acrobot.co.uk.

- ApplianSys -

ApplianSys specialises in server appliances, taking the central role in designing and building the appliance. Server appliances are servers with hardware and software designed and integrated for a specific task in a network. The server appliance approach offers a number of customer benefits compared with installing standard software applications on general purpose servers. These benefits include reduced costs of ownership and enhanced security. Savings are derived from lower upfront configuration and downstream maintenance costs, as well as lower costs associated with space, power and heat. With server appliances dedicated to one application the platform is also inherently secure. The London Technology Fund co-led a funding round of £620k in January 2007. A second close on 28 February 2007 took the total amount raised by ApplianSys to £720k.

For more information, please see latest news, our press release and www.appliansys.com.

- deltaDOT -

deltaDOT Ltd is a life science company that is developing and commercialising innovative enabling technologies for the separation and analysis of biomolecules. It was founded in 2000 and is a spin out from Imperial College of Science, Technology and Medicine, London. deltaDOT's core label free analysis technology, coupled with proprietary software algorithms, forms the technical basis of its products. This label free technology enables higher quality and faster separations compared to existing technologies. The increased performance enables the direct monitoring of unlabelled biomolecules, reducing the cost per analysis compared to conventional methods. deltaDOT addresses biomolecular separation applications within pharmaceutical, biotechnology, biodefence, food and drink quality, forensic science, diagnostic and academic markets. The London Technology Fund participated in a funding round of £6m in March 2006.

For more information, please see latest news, our press release and www.deltadot.com.

- Dexela -

Dexela is developing 3-D X-ray imaging technology known as Tomosynthesis and is initially focused on the early detection of breast cancer. The early detection of breast cancer using screening mammography significantly reduces mortality. However, conventional mammography still has a considerable rate of both false negatives and false positives, particularly in young women. Dexela’s innovative approach aims to reduce these false negatives and false positives, allowing the earlier detection of cancer while reducing the occurrence of call-backs. Dexela has developed techniques to acquire, process and visualise data and aims to play a central role in this field through collaborative agreements with medical device manufacturers. LTF invested in Dexela in July 2008 as part of a syndicate, including Close Ventures, which invested over £2.6m in aggregate.

For more information, please see latest news, our press release and www.dexelaimaging.com.

- Dynamic IT Management Services -

Dynamic IT Management Services is a supplier of specialist software for the foreign exchange market. Dynamic IT has developed a trade notification product, TradeSTP, which enables banks and brokers to deliver foreign exchange trade notifications directly to their clients’ applications. This system of ‘straight through processing’ offers enhanced speed and accuracy by eliminating the delay and risk of error associated with manual updating. TradeSTP has the potential to be a key component of the service offered to foreign exchange clients by banks and brokers. The London Technology Fund led a funding round of £800k in 2006 and has subsequently announced a partial exit.

For more information, please see latest news and our press release.

- Immune Targeting Systems -

Immune Targeting Systems (ITS) Ltd is a London-based biotech company developing synthetic vaccines for mutating viruses. The company’s lead programme is a synthetic universal influenza vaccine targeting all potential seasonal and pandemic flu strains. The thermostable vaccine potentially offers a new concept in flu vaccine supply and could represent a major breakthrough for governments wishing to create long-term vaccine stockpiles. Candidates for Hepatitis-B & C, HIV, and HPV-cancer await development funding or partners and the vaccine platform is applicable to a host of other infectious diseases as well as cancers. The London Technology Fund participated in ITS’s first significant funding round of £4.5m in July 2007 and a further funding round of up to £8.65m in February 2010. LTF was the only UK investor in an international syndicate including Novartis Venture Fund (Switzerland), HealthCap (Sweden) and Truffle Capital (France).

For more information, please see latest news, our press release and www.its-innovation.co.uk.

- Intellistream -

Intellistream has developed a platform for deploying interactive mobile video applications. This platform, Unistream™, was initially developed to operate over the video calling feature built into all 3G handsets, but has been expanded to cover IP-based smart-phone handsets (such as those which can use both 2.5G or 3G networks) via a downloaded client. The Company is initially targeting the security and safety market offering remote access to CCTV cameras from mobile phones. Possible applications include the corporate security markets, both SME businesses and also as an adjunct to existing large corporate and public security installations, and the domestic security markets. Additionally the Company's technology can be applied to a number of other applications including participation TV and gaming. The London Technology Fund led a funding round of £355k in November 2006. In April 2008 LTF announced the first close of a further funding round of up to £1m and this was followed by the appointment of a new chairman.

For more information, please see latest news and www.intellistream.co.uk.

- Novacem

Novacem, a spin-out from Imperial Innovations Group plc, is developing a cement which has the potential to transform the cement industry from being a significant emitter of CO2 to being an absorber of CO2. The annual production of over 2.5 billion tonnes of conventional Portland cement is already responsible for 5% of global CO2 emissions, and cement volumes are expected to double by 2050. In contrast to Portland cement, Novacem cement absorbs more CO2 over its life cycle than it emits. Novacem estimates that for every tonne of ordinary Portland cement replaced by Novacem cement, around 0.75 tonne of CO2 could be captured and stored indefinitely in construction products. In August 2009, LTF announced it was joint lead in a syndicate which included Imperial Innovations Group plc and the Royal Society Enterprise Fund, together investing over £1m.

For more information, please see latest news, our press release and www.novacem.com.

Please be sure to read this important legal information.